General Clinical Chemistry Analyzers and Accessories
Abcam PF-04929113 (SN x -5422), 100MG
MW 521.5 Da, Purity >99%. Potent and selective Hsp90 inhibitor (IC₅₀ = 50 nM). A Her-2 degradation inducer (IC₅₀ = 37 nM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2886721, BACE-1 inhibitor, 5MG
MW 390.4 Da, Purity >98%. Potent and selective BACE-1 inhibitor (IC₅₀ = 20.3 nM for recombinant hBACE-1). Human BACE2 is inhibited with an IC₅₀ of 10.2 nM. Does not inhibit other aspartyl proteases such as cathepsin D, pepsin, and renin. A potential agent to treat Alzheimer's Disease. Inhibits production of Aβ in HEK-293 Swe cells (IC₅₀ values are 18.5 nM and 19.7 nM for Aβ1-40 and Aβ1-42 respectively) and in PDAPP neuronal cells (IC₅₀ ~10 nM). Reduces dose-dependently brain levels of Aβ, C99 and sAPPβ in orally administered mouse model and plasma Aβ in dog model. Ppenetrates the blood-brain barrier.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Binimetinib, MEK1/2 inhibitor, 25MG
MW 441.2 Da, Purity >99%. Potent and selective allosteric inhibitor of MEK1/2. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SIS3, Smad3 inhibitor, 5MG
MW 490 Da, Purity >98%. Potent and selective Smad3 inhibitor. Selectively inhibits TGF-beta 1/ALK5-induced Smad3 phosphorylation. Inhibits the TGF-beta 1 effect on type I procollagen expression at the transcriptional levels via the Smad3-binding site. Has no effect on Smad2, p38, MAPK, ERK or PI 3-kinase signaling.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 50MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD1480, 5MG
MW 348.76 Da, Purity >98%. Novel, potent and selective small-molecule JAK2 inhibitor (IC₅₀ < 3 nM). It can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells. Also demonstrates >50-fold selectivity for JAK2 over JAK3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 5MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sulforhodamine 101 cadaverine trifluoroacetic salt, 5MG
MW 1381.8 Da, Purity >90%. Stable, bright red fluorescent label for proteins. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD-5069, 25MG
MW 476.5 Da, Purity >=98%. A potent and reversible CXCR2 chemokine receptor antagonist with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Umifenovir, 25MG
MW 477.4 Da, Purity >=95%. An indole derivative with broad-spectrum antiviral activity. It inhibits virus-mediated fusion with target membrane and blocks virus entry into target cells. It shows antiviral activity against many enveloped or non-enveloped RNA or DNA viruses with IC₅₀ values ranging from 0.41 to 16 uM. It (50 or 100 mg/kg/day) reduces mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Molecular dynamics and structural analysis show that Umifenovir may target SARS-CoV-2 spike glycoprotein and may block its trimerization which will reduce cell adherence and virus entry.
The product is subject to the following: Abcam Restricted Use Statement